These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 12022563

  • 1. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
    Dworschak M, Hiesmayr JM, Lassnigg A.
    Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
    [Abstract] [Full Text] [Related]

  • 2. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
    Kodityal S, Manhas AH, Udden M, Rice L.
    Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
    [Abstract] [Full Text] [Related]

  • 3. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P, Mayer R, MacDonald JL, Cleland AG, Hay-McKay C.
    Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
    [Abstract] [Full Text] [Related]

  • 4. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
    Gitlin SD, Deeb GM, Yann C, Schmaier AH.
    J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
    [Abstract] [Full Text] [Related]

  • 5. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
    Kanagasabay RR, Unsworth-White MJ, Robinson G, Bevan D, Farnsworth G, Haxby EJ, Smith EE.
    Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
    [Abstract] [Full Text] [Related]

  • 6. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Murphy GS, Marymont JH.
    J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
    [No Abstract] [Full Text] [Related]

  • 7. [Current treatment concepts in heparin-induced thrombocytopenia].
    Ranze O, Greinacher A.
    Dtsch Med Wochenschr; 1999 Jul 16; 124(28-29):865-73. PubMed ID: 10432950
    [No Abstract] [Full Text] [Related]

  • 8. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A, Meyer O, Hausmann H, Kuppe H, Hetzer R, Mertzlufft F.
    J Clin Anesth; 2000 Jun 16; 12(4):324-7. PubMed ID: 10960207
    [Abstract] [Full Text] [Related]

  • 9. [Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia].
    Brémaud M, De Maistre E, Junke E, Guerci A, Lalot JM, Longrois D, Lecompte T, Meistelman C.
    Ann Fr Anesth Reanim; 2004 Feb 16; 23(1):50-5. PubMed ID: 14980323
    [Abstract] [Full Text] [Related]

  • 10. [Heparin induced thrombocytopenia and anticoagulation in renal replacemant therapy].
    Steinfeldt T, Rolfes C.
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2008 Apr 16; 43(4):304-10; quiz 312. PubMed ID: 18409125
    [Abstract] [Full Text] [Related]

  • 11. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
    Grocott HP, Root J, Berkowitz SD, deBruijn N, Landolfo K.
    J Cardiothorac Vasc Anesth; 1997 Dec 16; 11(7):875-7. PubMed ID: 9412888
    [No Abstract] [Full Text] [Related]

  • 12. [Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
    Herzog S, Rath W, Kuhn W.
    Geburtshilfe Frauenheilkd; 1995 Mar 16; 55(3):164-6. PubMed ID: 7665065
    [Abstract] [Full Text] [Related]

  • 13. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
    Lindhoff-Last E, Betz C, Bauersachs R.
    Clin Appl Thromb Hemost; 2001 Oct 16; 7(4):300-4. PubMed ID: 11697713
    [Abstract] [Full Text] [Related]

  • 14. Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin.
    Keng TB, Chong BH.
    Br J Haematol; 2001 Aug 16; 114(2):394-6. PubMed ID: 11529862
    [Abstract] [Full Text] [Related]

  • 15. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
    Aouifi A, Blanc P, Piriou V, Bastien OH, Ffrench P, Hanss M, Lehot JJ.
    Ann Thorac Surg; 2001 Feb 16; 71(2):678-83. PubMed ID: 11235727
    [Abstract] [Full Text] [Related]

  • 16. Danaparoid sodium.
    Acostamadiedo JM, Iyer UG, Owen J.
    Expert Opin Pharmacother; 2000 May 16; 1(4):803-14. PubMed ID: 11249517
    [Abstract] [Full Text] [Related]

  • 17. [Heparin-induced type II thrombocytopenia within the scope of high dose chemotherapy with subsequent stem cell rescue].
    Sauer M, Gruhn B, Fuchs D, Altermann W, Zintl F.
    Klin Padiatr; 1998 May 16; 210(3):102-5. PubMed ID: 9629542
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.
    Horlait G, Minet V, Mullier F, Michaux I.
    Blood Coagul Fibrinolysis; 2017 Mar 16; 28(2):193-197. PubMed ID: 27100305
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.